Cardiorenalmetabolic

Latest News
December 20th 2024

FDA Rejects Sotagliflozin for Type 1 Diabetes; Lexicon Shifts Focus

December 20th 2024

Team-Based CINEMA Program Targets SDOH and Precision Care in Diabetes

December 20th 2024

Dr Yehuda Handelsman on How DCRM 2.0 Guidelines Refine CRM Disease Management

December 17th 2024

Top 5 Conference Coverage of 2024

December 17th 2024

Early Diabetes Screening in Pregnancy: Challenges and Opportunities

Video Interviews
View All
November 18th 2024

Innovations in Atherosclerosis Have Potential to Benefit Patients With CKD, HIV

September 5th 2024

Comprehensive Care: The Key to Managing Diabetes and Its Complexities

September 4th 2024

UPMC's Dr Manisha Jhamb Urges Better Kidney Disease Awareness, Integrated Care

August 2nd 2024

GLP-1 Agonists and the Gut-Brain Axis: A New Era in Obesity Management

July 8th 2024

2024 ASPC Congress on CVD Prevention to Be Held in August

June 15th 2024

Dr Kathryn Lindley Addresses Barriers to Women’s Heart Disease Diagnosis

Podcasts
View All
October 22nd 2024

Engage, Educate, Empower: Transforming Kidney Care

More News

Ozempic for diabetes | Image credit: mbruxelle – stock.adobe.com
December 17th 2024

Semaglutide Linked to Increased Risk of Rare, Debilitating Eye Condition

Hayden E. Klein
Patients with type 2 diabetes who use semaglutide have more than double the risk of severe optic nerve damage than those who don’t use the drug.
The top 5 diabetes content of 2024
December 16th 2024

Top 5 Most-Viewed Diabetes Content of 2024

Hayden E. Klein
This year’s top diabetes content focused on pediatric metabolic health, misconceptions about weight loss drugs, and more.
Highlights From ESC Congress 2024
December 12th 2024

ICYMI: Highlights From ESC Congress 2024

Hayden E. Klein
Top coverage from the 2024 European Society of Cardiology (ESC) Congress focused on screening, treatment, and equity in cardiovascular care.
Tirzepatide box sold as Mounjaro | Image credit: Cynthia – stock.adobe.com
December 5th 2024

How Tirzepatide Benefits Patients With Obesity-Related HFpEF

Hayden E. Klein
A SUMMIT trial analysis showed how tirzepatide improves cardiovascular and kidney health in patients with obesity-related heart failure with preserved ejection fraction (HFpEF).
Cardiovascular health | Image Credit: BillionPhotos.com - stock.adobe.com
November 25th 2024

Unfavorable Health-Related Social Needs Associated With Lower Cardiovascular Health Scores

Brooke McCormick
Adults with more unfavorable health-related social needs, such as unemployment or food insecurity, had a higher prevalence of low cardiovascular health, highlighting the importance of addressing social determinants to improve population health.
Doctor measuring patient's blood pressure | Image credit: Andrey Popov – stock.adobe.com
November 19th 2024

Intensive Blood Pressure Regimen Lowers CVD Risk for People With Diabetes

Connor Iapoce
Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with type 2 diabetes in the Blood Pressure Control Target in Diabetes trial.
Doctor writing prescription | Image credit: 18percentgrey – stock.adobe.com
November 18th 2024

SGLT2i Prescriptions for Heart Failure Are Rising, but Vary Across US

Hayden E. Klein
Of the 518 hospitals that had at least 10 eligible discharges, only 11 of them prescribed SGLT2 inhibitors to more than half of their patients.
AJMC Q&A with Dr Sanjula Jain | Background image credit: ipopba – stock.adobe.com
November 5th 2024

Rethinking Diabetes Care: Are New Therapies Adding Value or Cost?

Hayden E. Klein
Sanjula Jain, PhD, chief research officer at Trilliant Health, discusses the rapid adoption of glucagon-like peptide 1 inhibitors for diabetes and preventive care for obesity and late-onset diabetes.
Doctor holding stethoscope to red heart | Image credit: lenets_tan – stock.adobe.com
October 18th 2024

How the Clinical Trial Gender Gap Affects Women’s Heart Care

Hayden E. Klein
The history of women being left out of heart disease research has had significant consequences on heart health care today.
Navdeep Tangri, MD, PhD, FRCP
October 18th 2024

Population Health Strategies Are Vital for Tackling, Improving CKD Care

Kyle Munz
Navdeep Tangri, MD, PhD, FRCP, University of Manitoba, speaks to the value of population health strategies in clinical approaches to care delivery for patients with chronic kidney disease (CKD).
Aerial shot of neighborhood | Image credit: trekandphoto – stock.adobe.com
October 18th 2024

How Neighborhood Social Needs Drive Diabetes Care Disparities

Hayden E. Klein
Unmet social needs in certain neighborhoods contribute to disparities in diabetes care, leading to greater reliance on emergency services, fewer preventive measures, and higher rates of complications.
Woman at heart doctor | Image credit: Seventyfour – stock.adobe.com
October 15th 2024

Why Are We Still Seeing Gaps in Women’s Heart Care?

Hayden E. Klein
Women are still being excluded from cardiovascular research trials, and it has a lasting impact on heart disease treatment for women today.
Blood pressure monitor | Image credit: Photo Sesaon – stock.adobe.com
October 11th 2024

Remote Monitoring Program Cuts Heart Failure Readmissions in Half

Hayden E. Klein
UMass Memorial Health–Harrington Hospital reduced 30-day readmissions for congestive heart failure by 50% using artificial intelligence and remote care teams.
AJMC
October 10th 2024

Impact of Functional Recovery on Patients Having Heart Surgery

Richard J. Snow, DO, MPH Lauren McKown, JD, MPH Geoffrey Blossom, MD Karen Vogel, MPA Amy Creighton, MS Jason Shriver, OT Linda Will, APN Katie Lentz, PT, DPT Elizabeth Snow, MPH Teresa Caulin-Glaser, MD
This article describes the positive impact that actively managing functional recovery has on postacute placement for patients undergoing coronary artery bypass surgery.
Heart and stethoscope | Image credit: New Africa – stock.adobe.com
October 2nd 2024

Optimizing GDMT Could Prevent Over 1 Million HFrEF Deaths Annually

Hayden E. Klein
Despite being eligible for guideline-directed medical therapy (GDMT), tens of millions of patients across the globe are not receiving the heart failure care they need.
Diabetes | Image credit: Sherry Young – stock.adobe.com
October 1st 2024

What the Diabetes Health Economy Looks Like in 2024

Hayden E. Klein
The 2024 Trends Shaping the Health Economy report gave a past, present, and future look at diabetes care in the US and the role of obesity in these trends.
National Cholesterol Education month | Image Credit: © Waseem Ali Khan-stock.adobe.com
September 30th 2024

At-Home Cholesterol Screening Accessible Through New Program

Maggie L. Shaw
The innovative program from the Family Heart Foundation includes being able to order a free test kit for an at-home blood lipid panel and track your results online, as well as the ability to discuss the findings with care navigators and health care providers.
Heart failure | Image credit: irissca – stock.adobe.com
September 26th 2024

Adherence to 2021 ESC Heart Failure Guidelines Differed Across Practices

Hayden E. Klein
Inconsistent adherence to the guidelines led to delayed heart failure treatment optimization and underutilization of key therapies.
Hospital sign | Image credit: merrimonc – stock.adobe.com
September 25th 2024

Study Reveals High Variability in Hospital GDMT Scores, Outcomes, Costs

Hayden E. Klein
Hospitals that better utilized heart failure guideline-directed medical therapy (GDMT) had better patient outcomes, with lower mortality rates and costs.
DNA double helix | Image credit: Dr_Microbe – stock.adobe.com
September 24th 2024

The Role of Genetics in Cholesterol, Heart Disease Risk

Hayden E. Klein
A collection of research by Helen Hobbs, MD, highlights how genetic mutations influence cholesterol levels and impact heart disease risk, offering insights into lifelong cardiovascular health management.
Familial Hypercholesterolemia | Image credit: Richelle – stock.adobe.com
September 23rd 2024

A Decade of Progress in Familial Hypercholesterolemia Awareness, Treatment

Hayden E. Klein
On day 1 of the Family Heart Global Summit, speakers highlighted the critical need for awareness, early diagnosis, and innovative treatment options for familial hypercholesterolemia, sharing significant strides made in the field over the past decade.
The authors’ overall estimate of the current national prevalence of AF is at least 10.55 million individuals—more than 3 times what prior research estimated. | Image credit: Robert -stock.adobe.com
September 12th 2024

New Estimates Suggest Atrial Fibrillation 3 Times More Common Than Thought

Rose McNulty
New prevalence estimates of atrial fibrillation found that approximately 10.5 million US adults, or 5% of the population, have the condition.
AJMC
September 5th 2024

Antihyperglycemic Treatment Patterns for Chronic Kidney Disease and Type 2 Diabetes

Keith A. Betts, PhD Nikolaus G. Oberprieler, PhD, MSc, MBA Aozhou Wu, PhD Glen James, PhD Scott Beeman, PharmD Alain Gay, MD Xuanhao He, PhD David Vizcaya, PhD, MPH
This study characterized antihyperglycemic medication use after chronic kidney disease onset among patients with type 2 diabetes to uncover potential unmet needs in clinical practice.
Hot dogs with ketchup and mustard | Image credit: Mediteraneo – stock.adobe.com
September 4th 2024

Meat Consumption and Increased Diabetes Risk: Building on the Current Evidence Base

Hayden E. Klein
New findings add to the relationship between red meat and processed meat consumption and the risk of type 2 diabetes.
Inclisiran's twice-yearly cadence and physician administration have potential to improve adherence to treatment, which is a common challenge with cholesterol management. Image credit: Robert - stock.adobe.com
August 30th 2024

Inclisiran Significantly Lowers LDL-C in V-MONO Study

Rose McNulty
Twice-yearly inclisiran (Leqvio) monotherapy showed clinically meaningful and statistically significant LDL-C lowering in patients at low or moderate risk of atherosclerotic cardiovascular disease in the V-MONO study.
Doctor holding a heart | Image credit: Pana Studio - stock.adobe.com
August 30th 2024

Lipid-Lowering Therapies Beyond Statins: ESC 2024

Laura Joszt, MA
Research at the European Society of Cardiology Congress 2024 evaluated lipid-lowering therapy beyond statins alone in patients with high levels of low-density lipoprotein cholesterol.
Stethoscope around a red heart | Image credit: eggeeggjiew - adobe.stock.com
August 30th 2024

SGLT Inhibitors for Heart Failure by Duration of Diabetes: ESC 2024

Laura Joszt, MA
Regardless of duration of type 2 diabetes, sodium-glucose cotransporter inhibitors prevented cardiovascular events, according to research presented at the European Society of Cardiology Congress 2024.
CGM | Image credit: Andrey Popov – stock.adobe.com
Published: August 27th 2024 | Updated: August 27th 2024

FDA Expands Omnipod 5 AID System Label to Treat Type 2 Diabetes

Hayden E. Klein
The expanded approval for the Omnipod 5 system now allows automated insulin delivery (AID) for adults with type 2 diabetes, offering a new option for better glucose management without daily injections.
Red, yellow, and green trees reflecting memory loss or recovery | Image credit: freshidea – stock.adobe.com
August 27th 2024

SGLT2 Inhibitors, GLP-1 Agonists Similarly Reduce Dementia Risk for Patients With Diabetes

Hayden E. Klein
New findings add to the pile of research on the possible neuroprotective effects of drugs like dapagliflozin, empagliflozin, and dulaglutide for patients with type 2 diabetes.
Wegovy injections and packaging | Image credit: Ole – stock.adobe.com
August 24th 2024

Patients With Heart Failure May Benefit From Weight Loss Drug

Hayden E. Klein
New research indicates that the heart benefits of semaglutide can extend to those with heart failure.
123>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo